GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sysmex Corp (TSE:6869) » Definitions » Cash Flow from Financing

Sysmex (TSE:6869) Cash Flow from Financing : 円-9,013 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Sysmex Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Sysmex received 円270 Mil more from issuing new shares than it paid to buy back shares. It received 円4,000 Mil from issuing more debt. It paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received 円0 Mil from paying cash dividends to shareholders. It spent 円1 Mil on other financial activities. In all, Sysmex earned 円4,270 Mil on financial activities for the three months ended in Mar. 2024.


Sysmex Cash Flow from Financing Historical Data

The historical data trend for Sysmex's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sysmex Cash Flow from Financing Chart

Sysmex Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20,597.00 -20,253.00 -20,542.00 -24,234.00 -9,013.00

Sysmex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,888.00 -10,579.00 -2,230.00 2,102.00 1,694.00

Sysmex Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Sysmex's Cash from Financing for the fiscal year that ended in Mar. 2024 is calculated as:

Sysmex's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-9,013 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sysmex  (TSE:6869) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Sysmex's issuance of stock for the three months ended in Mar. 2024 was 円271 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Sysmex's repurchase of stock for the three months ended in Mar. 2024 was 円0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Sysmex's net issuance of debt for the three months ended in Mar. 2024 was 円4,000 Mil. Sysmex received 円4,000 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Sysmex's net issuance of preferred for the three months ended in Mar. 2024 was 円0 Mil. Sysmex paid 円0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Sysmex's cash flow for dividends for the three months ended in Mar. 2024 was 円0 Mil. Sysmex received 円0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Sysmex's other financing for the three months ended in Mar. 2024 was 円-1 Mil. Sysmex spent 円1 Mil on other financial activities.


Sysmex Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Sysmex's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sysmex (TSE:6869) Business Description

Traded in Other Exchanges
Address
1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, JPN, 6510073
Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas.

Sysmex (TSE:6869) Headlines

No Headlines